M3817
MegaCell™ RPMI-1640 Medium
without L-glutamine, liquid, sterile-filtered, suitable for cell culture
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
NACRES:
NA.75
UNSPSC Code:
12352207
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
sterility
sterile-filtered
form
liquid
technique(s)
cell culture | mammalian: suitable
impurities
endotoxin, tested
components
L-glutamine: no
shipped in
ambient
storage temp.
2-8°C
General description
MegaCell™ is a line of versatile media, formulated to significantly reduce the amount of serum required for cultivating mammalian cells in vitro. It is effective as a basal formulation for the growth and maintenance of adherent or suspension cell lines. When supplemented with 3% fetal bovine serum (FBS), MegaCell supports proliferative rates and maximal cell densities comparable, and in some cases superior, to the conventional basal formulation supplemented with 10% fetal bovine serum.
Application
MegaCell™ RPMI-1640 Medium has been used:
- as a component of the TSC medium for culturing trophoblast stem cells (TSC)
- as a component of 25 ng/ml FGF4 and 1 g/ml heparin (TSF4H medium) for culturing TSCs
- as a component of embryo-like structures (ETS) embryo medium and TS cell medium for culturing embryonic stem cells (ESCs) and TSCs
Preparation Note
Supplement with 4 mM L-glutamine (20 ml of 200 mM solution, G7513)
Legal Information
Sigma-Aldrich uses the MegaCell trademark pursuant to an agreement with Promega Corporation.
MegaCell is a trademark of Promega Corp.
Classe de stockage
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Jinhong Meng et al.
PloS one, 6(3), e17454-e17454 (2011-03-17)
Stem cell transplantation is a promising potential therapy for muscular dystrophies, but for this purpose, the cells need to be systemically-deliverable, give rise to many muscle fibres and functionally reconstitute the satellite cell niche in the majority of the patient's
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| M3817-500ML | 04061834050674 |